Johnson & Johnson (0R34.IL)
| Previous close | 152.40 |
| Open | 151.75 |
| Bid | 146.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 150.91 - 152.45 |
| 52-week range | 143.14 - 175.85 |
| Volume | |
| Avg. volume | 79,985 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 17 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Johnson & Johnson Insiders Sell US$6.8m Of Stock, Possibly Signalling Caution
The fact that multiple Johnson & Johnson ( NYSE:JNJ ) insiders offloaded a considerable amount of shares over the past...
Business WireJohnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
NEW BRUNSWICK, N.J., May 16, 2024--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with potential for an additional milestone payment.
- Yahoo Finance Video
Johnson & Johnson to sell remaining stake in Kenvue
Shares of Kenvue (KVUE) are trading slightly higher on Monday after Johnson & Johnson (JNJ) announced it would sell its remaining 9.5% stake in the company. Kenvue will not receive any money from the sale. Yahoo Finance Anchors Seana Smith and Jared Blikre break down the latest developments for these companies. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Nicholas Jacobino
